Get the Stockscreener App
9.40
10.98%
0.93
After Hours:
9.49
0.09
+0.96%
Immunitybio Inc stock is traded at $9.40, with a volume of 26.52M.
It is up +10.98% in the last 24 hours and down -4.37% over the past month.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
See More
Previous Close:
$8.47
Open:
$8.535
24h Volume:
26.52M
Relative Volume:
0.76
Market Cap:
$9.66B
Revenue:
$113.29M
Net Income/Loss:
$-351.47M
P/E Ratio:
-24.11
EPS:
-0.3898
Net Cash Flow:
$-309.19M
1W Performance:
+14.49%
1M Performance:
-4.37%
6M Performance:
+262.93%
1Y Performance:
+246.86%
1-Day Range:
$8.46
$9.54
1-Week Range:
$8.05
$9.54
52-Week Range:
$1.83
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
9.40 | 8.71B | 113.29M | -351.47M | -309.19M | -0.3898 |
VRTX
Vertex Pharmaceuticals Inc
|
451.24 | 115.33B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
736.53 | 77.48B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
681.85 | 41.09B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
306.66 | 41.40B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
143.98 | 29.32B | 606.42M | -1.28B | -997.58M | -6.403 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | BTIG Research | Buy |
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
View All
Immunitybio Inc Stock (IBRX) Latest News
ImmunityBio (NASDAQ:IBRX) Shares Up 11%Here's What Happened - MarketBeat
Why ImmunityBio Stock Is Up More Than 11% Today - Yahoo Finance
Why ImmunityBio Stock Is Up More Than 11% Today - The Motley Fool
ImmunityBio’s Asia Expansion: Macau Greenlights Anktiva for Bladder Cancer - StocksToTrade
ImmunityBio (IBRX) Announces NCCN Update Clinical Practice Guidelines to Include ANKTIVA for Papillary-Only NMIBC - Insider Monkey
ImmunityBio Receives Critical Approvals, Sees Significant Stock Gains - timothysykes.com
ImmunityBio's (IBRX) "Buy" Rating Reaffirmed at D. Boral Capital - MarketBeat
Can Anktiva's Label Expansion Unlock the Next Growth Phase for IBRX? - TradingView
ImmunityBio Inc stock surges on promising Phase 3 cancer vaccine data amid biotech rally - AD HOC NEWS
ImmunityBio, Inc. (NASDAQ:IBRX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
How Investors May Respond To ImmunityBio (IBRX) Securing First Asian Approval For ANKTIVA Via Macau Pathway - Yahoo Finance
Jim Cramer on ImmunityBio: “That Stock Is Part of the Magical Thinking Era” - Insider Monkey
Promising Biotech Stocks To Keep An Eye OnMarch 21st - MarketBeat
IBRX Stock Set To Snap 2 Weeks In Red: Anktiva Joins Global Blockbusters On Macau Drug List - Stocktwits
BTIG Sees Upside in ImmunityBio, Inc. (IBRX), Cites Strong 2026 ANKTIVA Sales Growth - Insider Monkey
ImmunityBio (NASDAQ:IBRX) Stock Price Down 4%Should You Sell? - MarketBeat
ImmunityBio Sees Unusually High Options Volume (NASDAQ:IBRX) - MarketBeat
First ANKTIVA approval in Asia gives bladder cancer drug a Macau entry - Stock Titan
ImmunityBio receives approval for ANKTIVA in Macau for bladder cancer - Investing.com
ImmunityBio receives Macau approval for bladder cancer drug By Investing.com - Investing.com India
ImmunityBio (IBRX) Is Up 12.8% After NCCN Expands ANKTIVA Bladder Cancer Guideline InclusionWhat's Changed - simplywall.st
ImmunityBio receives Macau approval for bladder cancer drug - Investing.com
ImmunityBio announces approval in Macau SAR, China for Anktiva - marketscreener.com
Immunitybio Announces Approval In Macau SAR, China For Anktiva - TradingView
IBRX Stock Rises Premarket As Founder Flags Early Anktiva Immune Data — Macau Nod Fuels Bull Case - Stocktwits
symbol__ Stock Quote Price and Forecast - CNN
ImmunityBio (NASDAQ:IBRX) Shares Up 3%Should You Buy? - MarketBeat
ImmunityBio gains as NCCN guidelines include new Anktiva indication - MSN
After years of delays, new deadline looms in 2028 for drug manufacturing plant in Dunkirk - Buffalo News
Assessing ImmunityBio (IBRX) Valuation After NCCN ANKTIVA Update And NK Cell Therapy Progress - simplywall.st
ImmunityBio Inc Trade Ideas — SWB:26CA - TradingView
ImmunityBio (IBRX) Clinical Trial for Lymphona Drug Follows $505M Convertible Note Change - MSN
ImmunityBio (NASDAQ:IBRX) Stock Price Up 4.3%Here's Why - MarketBeat
ImmunityBio (IBRX) Resubmits sBLA to FDA for ANKTIVA in Papillary Bladder Cancer - Insider Monkey
ImmunityBio (IBRX) climbs 7.3% as firm nears development of 'world bank of NK cells' - MSN
ImmunityBio Stock Jumps on Big Cancer Breakthrough - TipRanks
5 Most Buzzing Stocks to Buy with the Highest Upside Potential - Insider Monkey
ImmunityBio Highlights ANKTIVA Surge, FDA Papillary Filing and Key 2026 Milestones at Conference - MarketBeat
Heights Capital Management Inc. Purchases New Position in ImmunityBio, Inc. $IBRX - MarketBeat
IBRX Stock Rises After NCCN Guideline Update Expands ANKTIVA’s UseRetail Expects Sales To Surge - Stocktwits
Is 28.9% Fall In ImmunityBio (IBRX) Stock A Buying Opportunity? - Trefis
ImmunityBio's Anktiva Could See More Upside: My Updated Thoughts On Expansion - Seeking Alpha
ImmunityBio Stock To $6? - Trefis
ImmunityBio Stock Jumps As New Bladder Cancer Guideline Boosts Anktiva Use - Benzinga
NCCN Guideline Expansion Puts ANKTIVA And ImmunityBio Growth In Focus - Yahoo Finance
ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include AN - PharmiWeb.com
Will Anktiva Remain a Key Factor in ImmunityBio’s Revenue Expansion in 2026? - Bitget
ImmunityBio (NASDAQ:IBRX) Given "Buy" Rating at D. Boral Capital - MarketBeat
Why Is ImmunityBio (IBRX) Stock Jumping Today? ANKTIVA Gains NCCN Backing - Tokenist
Will Anktiva Continue to Drive ImmunityBio's Top-Line Growth in 2026? - Yahoo Finance
NCCN expands bladder cancer guidelines to include ImmunityBio drug - Investing.com
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.55%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):